India Pharma Outlook Team | Monday, 16 March 2026
Piramal Pharma Solutions has announced a major ADC batch milestone with the successful completion of its 1,500th antibody-drug conjugate (ADC) batch at its dedicated bioconjugate development and manufacturing facility in Grangemouth.
The milestone batch represents a commercial oncology ADC, highlighting the company’s growing role in delivering advanced cancer therapies to patients worldwide. Part of Piramal Pharma Ltd., Piramal Pharma Solutions has spent more than two decades building expertise in ADC development and manufacturing.
The company was the first contract development and manufacturing organization (CDMO) to commercially manufacture an ADC and the first ADC CDMO associated with a therapy approved by the U.S. Food and Drug Administration.
Also Read: India's Rare Disease Shift Driven by PRIP and PLI Policies
The ADC batch milestone reflects the strength of the Grangemouth facility, which provides integrated services ranging from proof-of-concept studies to clinical and commercial-scale production. The site also plays a central role in the company’s ADCelerate program, a rapid and integrated phase I ADC development platform designed to move projects quickly from research to GMP manufacturing across Piramal’s global network.
Over the years, the Grangemouth team has developed hundreds of unique bioconjugates and produced 1,500 ADC batches spanning clinical, commercial, and non-GMP production. Projects at the facility are supported by Piramal’s Science Collective, a group of subject matter experts that provides technical guidance and strategic direction.
The site also maintains strong regulatory compliance, with accreditations from both the U.S. Food and Drug Administration and the Medicines and Healthcare products Regulatory Agency, reinforcing Piramal’s commitment to delivering high-quality, life-saving bioconjugate therapies.
.jpg)
